Mitsubishi Tanabe Pharma is paying Medicago C$3 million up front in a vaccine research agreement.
The aim is to develop and commercialize at least three new vaccines, with MTPC providing funding for all R&D work.
Medicago will be eligible to receive up to a total of C$30 million in milestone payments as well as royalties on future sales.
Work on an RLP vaccine target will begin immediately, and additional targets under this master agreement are to be selected by the parties at a later date.
MTPC has the option to license an RLP vaccine target.
Medicago has developed a plant-based vaccine technology called Proficia.
Compared with traditional egg-based and cell production systems, plants are uniquely capable of efficient protein expression of different complexity levels and glycosylation patterns at high yields and low costs, the company reports. Greenhouse-based manufacturing facility conditions can be quickly built for rapid and economic scale-up in order to meet market demands, Medicago adds.